Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Brolucizumab in nAMD
NCT02507388Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Aug 2015
- Primary completion
- Sep 2016
- Modality
- scFv Fragments, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of brolucizumab in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Alcon Inc. Primary endpoints: Maximum Analyte Serum Concentration at Day 28, Time to Reach Maximum Analyte Serum Concentration at Day 28 and 4 more. Started Aug 2015; status: completed.
02
Drugs
brolucizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02507388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02507388.